Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

  1. Monin, L.
  2. Laing, A.G.
  3. Muñoz-Ruiz, M.
  4. McKenzie, D.R.
  5. del Molino del Barrio, I.
  6. Alaguthurai, T.
  7. Domingo-Vila, C.
  8. Hayday, T.S.
  9. Graham, C.
  10. Seow, J.
  11. Abdul-Jawad, S.
  12. Kamdar, S.
  13. Harvey-Jones, E.
  14. Graham, R.
  15. Cooper, J.
  16. Khan, M.
  17. Vidler, J.
  18. Kakkassery, H.
  19. Sinha, S.
  20. Davis, R.
  21. Dupont, L.
  22. Francos Quijorna, I.
  23. O'Brien-Gore, C.
  24. Lee, P.L.
  25. Eum, J.
  26. Conde Poole, M.
  27. Joseph, M.
  28. Davies, D.
  29. Wu, Y.
  30. Swampillai, A.
  31. North, B.V.
  32. Montes, A.
  33. Harries, M.
  34. Rigg, A.
  35. Spicer, J.
  36. Malim, M.H.
  37. Fields, P.
  38. Patten, P.
  39. Di Rosa, F.
  40. Papa, S.
  41. Tree, T.
  42. Doores, K.J.
  43. Hayday, A.C.
  44. Irshad, S.
  45. Montrer des auteurs +
Revue:
The Lancet Oncology

ISSN: 1474-5488,  1470-2045

Année de publication: 2021

Volumen: 22

Número: 6

Pages: 765-778

Type: Article

DOI: 10.1016/S1470-2045(21)00213-8 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus